Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 07, 2022 09:04 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
June 02, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
May 26, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting

Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE...
May 20, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
May 13, 2022 06:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
May 10, 2022 09:17 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
May 03, 2022 09:17 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex

Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
April 29, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
April 12, 2022 10:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
April 05, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®

Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...